Paper Details

  1. Home
  2. Paper Details

Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.

Author: , AoyamaS, BedardP, BorrelliE, ChaseT N, HauserR A, IchimuraM, IkedaK, IshiiA, JennerP, KandaT, KaseHiroshi, KogaK, KoikeN, KurokawaM, KuwanaY, MoriA, NakamuraJ, NonakaH, OchiM, RichardsonP J, SakiM, ShimadaJ, ShindouT, ShiozakiS, SuzukiF, TakedaM, YanagawaK

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

KW6002, a selective adenosine A2A receptor antagonist, was developed as a novel non-dopaminergic therapy for Parkinson's disease (PD). In animal models, KW6002 provided symptomatic relief from parkinsonian motor deficits without inducing dyskinesia. Clinical studies showed promising results in patients with advanced PD, demonstrating motor symptom relief without motor side effects. This development represents a significant advancement in non-dopaminergic approaches to PD therapy.
Paper Details　
Original Abstract of the Article :
Research and development of the adenosine A2A receptor selective antagonist KW6002 have focused on developing a novel nondopaminergic therapy for Parkinson's disease (PD). Salient pharmacologic features of KW6002 were investigated in several animal models of PD. In rodent and primate models, KW6002 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1212/01.wnl.0000095219.22086.31

データ提供：米国国立医学図書館（NLM）

KW6002: A New Oasis in the Desert of Parkinson's Disease

Parkinson's disease, a neurodegenerative disorder that affects movement, can significantly impact a person's ability to live a full and independent life. This research investigates the potential of KW6002, a selective adenosine A2A receptor antagonist, as a novel nondopaminergic therapy for Parkinson's disease. The study explores the efficacy of KW6002 in improving motor function and reducing the side effects associated with traditional dopaminergic therapies.

KW6002: A Beacon of Hope in the Desert of Parkinson's

The researchers found that KW6002 effectively reduced parkinsonian motor deficits in both rodent and primate models without inducing dyskinesia or exacerbating existing dyskinesia. The study suggests that KW6002 may provide a safe and effective treatment option for individuals with Parkinson's disease, particularly those experiencing motor complications associated with traditional therapies.

KW6002: A Promising Path in the Desert of Parkinson's Treatment

This research offers a beacon of hope for individuals with Parkinson's disease, highlighting the potential of KW6002 as a novel therapeutic approach. The study's findings suggest that KW6002 may provide a safe and effective treatment option, offering relief from motor symptoms without the side effects associated with traditional dopaminergic therapies.

Dr.Camel's Conclusion

This research takes us on a journey through the desert of Parkinson's disease, highlighting the potential of KW6002 as a promising new treatment. Just as a camel caravan can find a cool oasis after a long journey, KW6002 may offer a much-needed respite for those struggling with Parkinson's disease. The study's findings provide hope for a future where individuals with Parkinson's can live with greater independence and quality of life.

Date :
  1. Date Completed 2004-02-11
  2. Date Revised 2019-05-14
Further Info :

Pubmed ID

14663020

DOI: Digital Object Identifier

10.1212/01.wnl.0000095219.22086.31

Related Literature

Article Analysis
・Side Effects of istradefylline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.